Morsef Pharmaceuticals Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 07-07-2024
- Paid Up Capital ₹ 0.10 M
as on 07-07-2024
- Company Age 25 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.00 M
as on 07-07-2024
- Revenue 43.10%
(FY 2022)
- Profit 83.54%
(FY 2022)
- Ebitda 5.29%
(FY 2022)
- Net Worth 31.40%
(FY 2022)
- Total Assets -11.46%
(FY 2022)
About Morsef Pharmaceuticals
The Corporate was formerly known as Cibien International Private Limited. The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹7.00 M.
Himanshu Bhatt and Shilpa Bhatt serve as directors at the Company.
- CIN/LLPIN
U51900MH1999PTC120206
- Company No.
120206
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jun 1999
- Date of AGM
01 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Morsef Pharmaceuticals Private Limited offer?
Morsef Pharmaceuticals Private Limited offers a wide range of products and services, including Pharmaceutical Machinery & Equipment, Pharmaceutical Machines.
Who are the key members and board of directors at Morsef Pharmaceuticals?
Board Members(2)
Financial Performance and Corporate Structure Insights of Morsef Pharmaceuticals.
Morsef Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 43.1% increase. The company also saw a substantial improvement in profitability, with a 83.54% increase in profit. The company's net worth Soared by an impressive increase of 31.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Morsef Pharmaceuticals?
In 2020, Morsef Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
5 years 7 months Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Feb 2021 | ₹7.00 M | Open |
How Many Employees Work at Morsef Pharmaceuticals?
Unlock and access historical data on people associated with Morsef Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Morsef Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Morsef Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
